Pharmacotherapy of adult attention deficit/hyperactivity disorder: Review of evidence-based practices and future directions

Expert Opinion on Pharmacotherapy

Volumn 9, Issue 8, 2008, Pages 1299-1310

  Tcheremissine, Oleg V ^a   Salazar, J Octavio ^a  

^a CAROLINAS MEDICAL CENTER   (United States)

Author keywords

Adults; Attention deficit hyperactivity disorder; Diagnosis; Pharmacotherapy

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; AMFEBUTAMONE; AMPHETAMINE; ANTIDEPRESSANT AGENT; ATOMOXETINE; CENTRAL STIMULANT AGENT; CLONIDINE; DESIPRAMINE; DEXAMPHETAMINE; GUANFACINE; METHYLPHENIDATE; MODAFINIL; MONOAMINE OXIDASE INHIBITOR; PAROXETINE; PLACEBO; PSYCHOSTIMULANT AGENT; SELEGILINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE; CENTRAL NERVOUS SYSTEM AGENTS;

AGITATION; ALCOHOLISM; AMNESIA; ANGER; ANOREXIA; ANXIETY; ATTENTION DEFICIT DISORDER; BIOEQUIVALENCE; CHILDHOOD DISEASE; CLINICAL TRIAL; COGNITIVE DEFECT; COMORBIDITY; CONSTIPATION; CONTROLLED DRUG RELEASE; DEPRESSION; DOSE RESPONSE; DROWSINESS; DRUG CAPSULE; DRUG DOSAGE FORM; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ERUPTION; DRUG FORMULATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG MEGADOSE; DRUG MIXTURE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EMOTIONAL DISORDER; EVENING DOSAGE; EVIDENCE BASED MEDICINE; FATIGUE; GASTROINTESTINAL SYMPTOM; HALLUCINATION; HEADACHE; HEART RATE; HUMAN; HYPERACTIVITY; HYPERTENSION; IMPULSIVENESS; INSOMNIA; IRRITABILITY; LETHARGY; LOW DRUG DOSE; MANIA; MEDLINE; MENTAL DISEASE; MOOD CHANGE; MORNING DOSAGE; NAUSEA; NERVOUSNESS; NONHUMAN; OPTIMAL DRUG DOSE; ORTHOSTATIC HYPOTENSION; PATIENT COMPLIANCE; PSYCHOPHARMACOTHERAPY; PSYCINFO; REVIEW; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SINGLE DRUG DOSE; SUBSTANCE ABUSE; SUICIDAL IDEATION; SYMPTOMATOLOGY; TABLET FORMULATION; TACHYCARDIA; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN; XEROSTOMIA; ADULT; AGE; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGE FACTORS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM AGENTS; EVIDENCE-BASED MEDICINE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 45549102509     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.9.8.1299     Document Type: Review

References (96)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd edition. American Psychiatric Association, Washington DC; 1980
2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th edition. American Psychiatric Association, Washington DC; 2000
3. Froehlich TE, Lanphear BP, Epstein JN, et al. Prevalence, recognition, and treatment of attention-deficit/hyperactivity disorder in a National sample of US children. Arch Pediatr Adolesc Med 2007;161:857-64
4. Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: results from the national Comorbidity Survey Replication. Am J Psychiatry 2006;163:716-23
5. Biederman J, Wilens TE, Mick E, et al. Young adult of attention deficit hyperactivity disorder: a controlled 10-year follow-up study. Psychol Med 2006;36:167-79
6. Faraone SV, Biederman J, Mick E. The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies. Psychol Med 2006;36:159-65
7. Murphy P. Cognitive functioning in adults with attention deficit/ hyperactivity disorder. J Atten Disord 2002;5:203-9
8. Barkley RA, Guevremont DC, Anastopoulos AD, et al. Driving-related risks and outcomes of attention deficit hyperactivity disorder in adolescents and young adults: a 3 - 5 years follow up survey. Pediatrics 1993;92:212-8
9. Biederman J, Faraone SV, Spencer TJ, et al. Functional impairments in adults with self reports of diagnosed ADHD. A controlled study of 1001 adults in the community. J Clin Psychiatry 2006;67:524-40
10. Fischer M, Barkley RA, Smallish L, et al. Young adult follow-up of hyperactive children: self-reported psychiatric disorders, comorbidity, and the role of childhood conduct problems and teen CD. J Abnorm Child Psychol 2002;30:463-75
11. Murphy K, Barkley RA. Attention deficit hyperactivity disorder adults: comorbidities and adaptive impairments. Compr Psychiatry 1996;37:393-401
12. Barkley RA. ADHD and the nature of self-control. New York: Guilford Press; 1997
13. Pliszka S, McCracken J, Maas J. Catecholamines in attention-deficit hyperactivity disorder: current perspectives. J Am Acad Child Adolesc Psychiatry 1996;35:264-72
14. Wender PH, Reimherr FW, Wood DR, et al. A controlled study of methylphenidate in the treatment of attention-deficit disorder, residual type, in adults. Am J Psychiatry 1985;142:547-52
15. Spencer T, Biederman J, Wilens T, et al. Efficacy of mixed amphetamines salts compound in adults with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 2001;58:775-82
16. Spencer T, Wilens T, Biederman J, et al. A double-blind comparison of methylphenidate and placebo in adults with childhood-onset attention-deficit hyperactivity disorder. Arch Gen Psychiatry 1995;52:434-43
17. Barkley R, Duraul G, McMurray M. Attention deficit disorder with and without hyperactivity: clinical response to three dose levels of methylphenidate. Pediatrics 1991;87:519-31
18. Wood DR, Reimherr FW, Wender PH, et al. Diagnosis and treatment of minimal brain dysfunction in adults: a preliminary report. Arch Gen Psychiatry 1976;33:1453-60
19. Spencer T, Biederman J, Wilens T, et al. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 2005;57(5):456-63
20. Biederman J, Mick E, Surman C, et al. A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/ hyperactivity disorder. Biol Psychiatry 2006;59:829-35
21. Jain U, Hechtman L, Weiss M, et al. Efficacy of a novel biphasic controlled-release methylphenidate formula in adults with attention-deficit/hyperactivity disorder: results of a double-blind, placebo-controlled crossover study. J Clin Psychiatry 2007;68(2):268-77
22. Volkow ND, Fowler JS, Gatley SJ, et al. PET evaluation of the dopamine system of human brain. J Nucl Med 1996;37:1242-56
23. Patrick KS, Caldwell RW, Ferris RM, Breese GR. Pharmacology of the enantiomers of threo-methylphenidate. J Pharmacol Exp Ther 1987;241:1219-23
24. Thall E. When drug molecules look in the mirror. J Chem Educ 1996;73:481-4
25. Quinn D, Wigal S, Swanson J, et al. Comparative psychodynamics and plasma concentrations of d-threo-methylphenidate hydrochloride after single doses of d-threo-methylphenidate hydrochloride and d,l-treo-methylphenidate hydrochloride in a double-blind, placebo-controlled, crossover laboratory school study in children attention deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2004;43:1422-9
26. Spencer TJ, Adler LA, McGough JJ, et al. Efficacy and safety of dexmethylphenidate extended-release capsules in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 2007;61:1380-7
27. Robinson LM, Skaer TL, Sclar DA, et al. Is attention deficit hyperactivity disorder increasing among girls in the US? Trends in diagnosis and the prescribing of stimulants. CNS Drugs 2002;16:129-37
28. Tulloch SJ, Zhang Y, McLean A, Wolf KN. SLI 381 (Aderall XR), a two component, extended release formulation of mixed amphetamine salts: bioavailability of three tests formulations and comparison of fasted, fed, and sprinkled administration. Pharmacotherapy 2002;22:1405-15
29. McCraken JT, Biederman J, Greenhill LL, at al. Analog classroom assessment of a once-daily mixed amphetamine formulation, SLI381 (Adderal XR), in children with ADHD. J Am Acad Child Adolesc Psychiatry 2003;42:673-83
30. Biederman J, Lopez FA, Boellner SW, Chandler MC. A randomized, double-blind, placebo-controlled, parallel group study of SLI381 (Adderal XR) in children with attention-deficit/hyperactivity disorder. Pediatrics 2002;110:258-66
31. Weisler RH, Biederman J, Spencer TJ, et al. Mixed amphetamine salts extended release in the treatment of adult ADHD: a randomized, controlled trial. CNS Spectr 2006;11:625-39
32. Clausen SB, Read SC, Tulloch SJ. Single and multiple-dose pharmacokinetics of an oral mixed amphetamine salts extended-release formulation in adults. CNS Spectr 2005;10(12 Suppl 20):6-15
33. Wilens TE, Gignac M, Sweezy A, et al. Characteristics of adolescents and young adults with ADHD who divert or misuse their prescribed medications. J Am Acad Child Adolesc Psychiatry 2006;45:408-14
34. Biederman J, Spencer TJ, Wilens TE, et al. Treatment of ADHD with stimulants medications: response to Nissen perspective in the New England Journal of Medicine. J Am Child Adolesc Psychiatry 2006;45:1147-50
35. Greenhill L. Attention-deficit/hyperactivity disorder: the stimulants. Child Adolesc Psychiatr Clin North Am 1995;4:123-68
36. Levin FR, Evans SM, Vosburg SK, et al. Impact of attention-deficit/ hyperactivity disorder and other psychopathology on treatment retention among cocaine abusers in a therapeutic community. Addict Behav 2004;29:1875-82
37. Wilens TE. Impact of ADHD and its treatment on substance abuse in adults. J Clin Psychiatry 2004;65(Suppl 3):38-45
38. Biederman J, Wilens TE, Mick E, et al. Does attention-deficit/ hyperactivity disorder impact the developmental course of drug and alcohol abuse and dependence? Biol Psychiatry 1998;44:269-73
39. Wilens T, Faraone SV, Biederman J, et al. Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of literature. Pediatrics 2006;15:476-95
40. Faraone SV, Wilens T. Does stimulant treatment lead to substance abuse disorders? J Clin Psychiatry 2003;64(Suppl 11):9-13
41. Devoto P, Flore G, Pani L, et al. Evidence for co-release of noradrenaline and dopamine from noradrenergic neurons in the cerebral cortex. Mol Psychiatry 2001;6:657-64
42. Heil SH, Holmes HW, Bickel WK, et al. Comparison of the subject-rated, physiological and psychomotor effects of atomoxetine and methylphenidate in recreational drug abusers. Drug Alcohol Depend 2002;67:149-56
43. Michelson D, Adler L, Spencer T, et al. Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry 2003;53:112-20
44. Wender PH, Reimherr FW, Wood DR. Attention deficit disorder (minimal brain dysfunction) in adults: a replication study of diagnosis and drug treatment. Arch Gen Psychiatry 1981;38:449-56
45. Available from: http://dea.gov./pubs/scheduling.html
46. Stahl SM. Psychopharmacology of wakefulness: pathways and neurotransmitters. J Clin Psychiatry 2002;63:551-2
47. Scammell TE, Estabrooke IV, McCarthy MT, et al. Hypothalamic arousal regions activated during modafinil-induced wakefulness J Neurosci 2000;20(22):8620-8
48. Taylor FB, Russo J. Efficacy of modafinil compared to dextroamphetamine for the treatment of attention deficit hyperactivity disorder in adults. J Child Adolesc Psychopharmacol 2000;10:311-20
49. Turner DC, Clark L, Dowson J, et al. Modafinil improves cognition and response inhibition an adult attention-deficit/hyperactivity disorder. Biol Psychiatry 2004;55:1031-40
50. Metha MA, Goodyer IM, Sahakian BJ. Methylphenidate improves working memory and set-shifting in AD/HD: relationship to baseline memory capacity. J Child Psychol Psychiatry 2004;45:293-305
51. FDA Safety Information, 2007. Available from: http://www.fda.gov/ medwatch/safety/2007/safety07.htm#Provigil [Last accessed 10 April 2008]
52. Aston-Jones G, Rajkowski J, Cohen J. Locus coeruleus and regulation of behavioral flexibility and attention. Prog Brain Res 2000;126:165-82
53. Gerra G, Caccavari R, Fontanesi B, et al. Alpha-2-adrenoreceptor sensitivity in heroin addicts with and without previous attention deficit disorder/hyperactivity and conduct disorder. Neuropsychobiology 1994;30:15-9
54. Li B-M, Mao Z-M, Wang M, Mei Z-T. Alpha-2 adrenergic modulation of prefrontal cortical neuronal activity related to spatial working memory in monkeys. Neuropsychopharmacology 1999;21:601-10
55. Ma C-L, Arnsten A, Li B-M. Locomotor hyperactivity induced by blockade of prefrontal cortical alpha-2-adrenoreceptors in monkeys. Biol Psychiatry 2005;57:192-5
56. Agarwal V, Sitholey P, Kumar S, Prasad M. Double-blind, placebo-controlled trial of clonidine in hyperactive children with mental retardation. Ment Retard 2001;39:259-67
57. Masi G. Pharmacotherapy of pervasive developmental disorders in children and adolescents. CNS Drugs 2004;18:1031-52
58. Connor DE, Barkley RA, Davis HT. A pilot study of methylphenidate, clonidine, or the combination in ADHD comorbid with aggressive oppositional defiant or conduct disorder. Chin Pediatr (Phila) 2000;39:15-25
59. Uhlen S, Porter AC, Neubig RR. The novel alpha-2 adrenergic radioligand [3H]-MK912 is alpha-2C selective among human alpha-2A, alpha-2B and alpha-2C adrenoreceptors. J Pharmacol Exp Ther 1994;271:1558-65
60. Arnsten AFT, Steere JC, Hunt RD. The contribution of alpha-2 noradrenergic mechanisms to prefrontal cortical cognitive function: potential significance to attention deficit hyperactivity disorder. Arch Gen Psychiatry 1996;53:448-55
61. Taylor FB, Russo J. Comparing guanfacine and dextroamphetamine for the treatment of adult attention-deficit/hyperactivity disorder. J Clin Psychopharmacol 2001;21:223-8
62. Aston-Jones G, Chiahng C, Alexinsky T. Discharge of noradrenergic locus coeruleus neurons in behaving rats and monkeys suggestions a role in vigilance. Prog Brain Res 1991;88:501-20
63. Sagvolden T. The alpha2A adrenoreceptor agonist guanfacine improves sustained attention and reduces overactivity and impulsiveness in an animal model of attention-deficit/hyperactivity disorder (ADHD). Behav Brain Funct 2006;2:41
64. Swearingen D, Pennick M, Shojaei A, et al. A phase I, randomized, open-label, crossover study of the single-dose pharmacokinetic properties of guanfacine extended-release 1-, 2-, and 4-mg tablets in healthy adults. Clin Ther 2007;4:617-25
65. Maidment ID. The use of antidepresaants to treat attention deficit hyperactivity disorder in adults. J Psychopharmacol 2003;17(3):332-6
66. Ascher JA, Cole JO, Colin J, et al. Bupropion: a review of its mechanisms of antidepressants activity. J Clin Psychiatry 1995;56:395-401
67. Casat CD, Pleasants DZ, Van Wyck Fleet J. A double-blind trial of bupropion in children with attention deficit disorder. Psychopharmacol Bull 1987;23:120-2
68. Wender PH, Reimherr FW. Bupropion treatment of attention-deficit hyperactivity disorder in adults. Am J Psychiatry 1990;147:1018-20
69. Wilens TE, Spencer TJ, Biederman J, et al. A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. Am J Psychiatry 2001;158:282-8
70. Kuperman S, Perry PJ, Gaffney GR, et al. Bupropion SR versus methylphenidate versus placebo for attention deficit hyperactivity disorder in adults. Ann Clin Psychiatry 2001;13:129-34
71. Gastfriend DR, Biederman J, Jellinek MS. Desipramine in the treatment of adolescents with attention deficit disorder. Am J Psychiatry 1984;141:906-8
72. Biederman J, Gastfriend DR, Jellinek MS. Desipramine in the treatment of adolescents with attention deficit disorder. J Clin Psychopharmacol 1986;6:359-63
73. Wilens T, Biederman J, Prince J, et al. Six-week, double-blind, placebo-controlled study of desipramine for adult attention deficit hyperactivity disorder. Am J Psychiatry 1996;153:1147-53
74. Weiss M, Hechtman L; and The Adult ADHD Research Group. A randomized double-blind trial of paroxetine and/or dextroamphetamine and problem-focused therapy for attention-deficit/hyperactivity disorder in adults. J Clin Psychiatry 2006;67:611-9
75. Zametkin AJ, Liotta W. The neurobiology of attention-deficit/ hyperactivity disorder. J Clin Psychiatry 1998;59:17-23
76. Adler LA, Resnick S, Kunx M, Devinsky O. Open-label trial of venlafaxine in adults with attention deficit disorder. Psychopharmacol Bull 1995;31:785-8
77. Findling RL, Schwartz MA, Flannery DJ, Manos MJ. Venlafaxine in adults with attention-deficit/hyperactivity disorder: an open clinical trial. J Clin Psychiatry 1996;57:184-9
78. Upadhyaya HP, Brady KT, Sethuraman G, et al. Venlafaxine treatment of patients with comorbid alcohol/cocaine abuse and attention-deficit/ hyperactivity disorder: a pilot study. J Clin Psychopharmacol 2001;21(1):116-8
79. Zametkin AJ, Rapoport JL, Murphy DL, et al. Treatment of hyperactive children with monoamine oxidase inhibitors. I. Clinical efficacy. Arch Gen Psychiatry 1985;42:962-6
80. Ernst M, Liebenauer LL, Jons PH, et al. Selegiline in adults with attention deficit hyperactivity disorder: clinical efficacy and safety. Psychopharmacol Bull 1996;32(3):327-34
81. Knoll J. The pharmacology of selegiline ((-) deprenyl). New aspects. Acta Neurol Scand 1989;126:83-91
82. Adler NE, Snibbe AC. The role of psychosocial processes in explaining the gradient between socioeconomic status and health. Curr Direct Psychol Sci 2003;12:119-23
83. Firestone P. factors associated with children's adherence to stimulant medication. Am J Orthopsychiatry 1982;52:447-57
84. Charach A, Ickowicz A, Schachar R. Stimulant treatment over five years: adherence, effectiveness, and adverse effects. J Am Acad Child Adolesc Psychiatry 2004;43:559-67
85. Perwien A, Hall J, Swensen A, Swindle R. Stimulant treatment patterns and compliance in children and adults with newly treated attention-deficit/hyperactivity disorder. J Mang Care Pharm 2004;10:122-9
86. Miller AR, Lalode CE, McGrail KM. Children's persistence with methylphenidate therapy: a population-based study. Can J Psychiatry 2004;49:761-8
87. Adler LA, Chua HC. Management of ADHD in adults. J Clin Psychiatry 2002;63(Suppl 12):29-35
88. Wilens TE, Spencer TJ, Biederman J. A review of the pharmacotherapy of adults with attention-deficit/hyperactivity disorder. J Atten Disord 2002;5:189-202
89. Murphy P. Cognitive functioning in adults with attention deficit/ hyperactivity disorder. J Atten Disord 2002;5:203-9
90. Faraone SV, Biederman J, Monuteaux M, et al. Attention deficit hyperactivity disorder and learning disability: a prospective four-year follow-up study. J Atten Disord 2001;3:23-5
91. Faraone SV, Biederman J, Monuteaux M, et al. A psychometric measure of learning disability predicts educational failure four years later in boys with attention deficit hyperactivity disorder. J Atten Disord 2001;4:220-30
92. Seideman LJ, Biederman J, Faraone SV, et al. Effects of family history and comorbidity on the neuropsychological performance of children with ADHD: preliminary findings. J Am Acad Child Adolesc Psychiatry 1995;34:1015-24
93. Willens TE, Verlinden MH, Adler LA, et al. ABT-089, a neuronal nicotinic receptor partial agonist, for the treatment of attention-deficit/ hyperactivity disorder in adults: results of a pilot study. Biol Psychiatry 2006;59:1065-70
94. Wilens TE, Decker MW. Neuronal receptor agonists for the treatment of attention-deficit/hyperactivity disorder: focus on cognition. Biochem Pharmacol 2007;74(8):1212-23
95. Rostain AL, Ramsay JR. A combined treatment approach for adults with ADHD: results of an open study of 43 patients. J Atten Disord 2006;10(2):150-9
96. Safren SA, Otto MW, Sprich S, et al. Cognitive-behavioral therapy for ADHD in medication-treated adults with continued symptoms. Behav Res Ther 2005;43:831-42